JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolf, B. B.
Right arrow Articles by Green, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolf, B. B.
Right arrow Articles by Green, D. R.

J Biol Chem, Vol. 274, Issue 29, 20049-20052, July 16, 1999

MINIREVIEW
Suicidal Tendencies: Apoptotic Cell Death by Caspase Family Proteinases*

Beni B. WolfDagger § and Douglas R. GreenDagger parallel

From the Dagger  Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology, San Diego, California 92121 and the § Department of Internal Medicine, University of California, San Diego, California 92103

    INTRODUCTION
TOP
INTRODUCTION
Caspases and Apoptosis
Caspase Structure
Caspase Activation
Caspases and the Apoptotic...
Conclusion
REFERENCES

Certain proteases are not merely degradative enzymes but are highly regulated signaling molecules that control critical biological processes via specific limited proteolysis. Caspase proteinases and their central role in apoptotic cell death provide a prime example of this concept. These cysteine proteinases exist as latent zymogens; however, once activated by apoptotic signals, they systematically dismantle and package the cell by cleaving key cellular proteins solely after aspartate residues. Here we review caspase proteinases with an emphasis on their structure, activation, and critical role in the apoptotic mechanism.

    Caspases and Apoptosis
TOP
INTRODUCTION
Caspases and Apoptosis
Caspase Structure
Caspase Activation
Caspases and the Apoptotic...
Conclusion
REFERENCES

In 1993, researchers discovered that the Caenorhabditis elegans cell death gene, ced-3, had remarkable sequence similarity to interleukin-1beta -converting enzyme (caspase-1), a mammalian proteinase responsible for proteolytic maturation of pro-interleukin-1beta (1-3). This seminal finding delineated the first two members of the caspase family and suggested that these proteinases might function during apoptosis. Subsequent studies identified over a dozen caspase family members important for apoptosis and/or inflammation (Table I) (4-6) (reviewed in Refs. 7 and 8).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Caspase characteristics

Several lines of evidence indicate that caspases are important for apoptosis. First, caspase activation correlates with the onset of apoptosis and caspase inhibition attenuates apoptosis (7-10). Second, C. elegans mutants lacking the worm caspase, CED-3, have a complete absence of developmental programmed cell death (11). More recently, targeted deletion of caspase genes has shown a definitive role for caspases in apoptosis and inflammation (reviewed in Ref. 12). Animals deficient in caspase-3, caspase-8, or caspase-9 die perinatally because of profound defects in developmental programmed cell deaths (12, 13). Similarly, deletion of the gene for Drosophila caspase-1 causes larval lethality and also promotes melanotic tumor development (14). Caspase-2-deficient mice develop normally, but cells from these animals show diminished or enhanced apoptosis, depending on their tissue of origin (15). These differences may relate to tissue-specific expression of pro- and anti-apoptotic caspase-2 isoforms. By contrast, caspase-1 and caspase-11 knockout mice have defective interleukin-1beta production but develop normally and have minimal apoptotic defects (12, 16).

    Caspase Structure
TOP
INTRODUCTION
Caspases and Apoptosis
Caspase Structure
Caspase Activation
Caspases and the Apoptotic...
Conclusion
REFERENCES

Sequence analysis and x-ray crystallography data suggest that all caspases share a common structure (4-8, 17-20). Each zymogen contains an N-terminal prodomain, a large subunit containing the active site cysteine within a conserved QACXG motif, and a C-terminal small subunit. An aspartate cleavage site separates the prodomain from the large subunit, and an interdomain linker containing one or two aspartate cleavage sites separates the large and small subunits. Activation accompanies proteolysis of the interdomain linker and usually results in subsequent removal of the prodomain. The active enzymes function as tetramers, consisting of two large/small subunit heterodimers (17-20). The heterodimers each contain an active site composed of residues from both the small and large subunits. Each active site contains a positively charged S1 subsite that binds the substrate's negatively charged P1 aspartate (17-20). This S1 binding site is highly conserved; therefore, all caspases cleave solely after aspartate residues.

The individual caspases have two major structural differences. First, the predicted S2-S4 substrate binding sites vary significantly, resulting in varied substrate specificity in the P2-P4 positions, despite an absolute requirement for aspartate in the P1 position (4-8, 17-20). Thornberry et al. (21) recently defined the optimal tetrapeptide substrate specificity for 10 caspases using a synthetic combinatorial peptide library. The sequence preferences generally correlate with caspase function as apoptotic initiators, apoptotic executioners, and cytokine processors (Table I). Note that the tetrapeptide preferences listed in Table I are not absolute and that the preferences do not represent kinetic values that can be directly compared. For example, caspase-3 and caspase-7 both prefer DEXD-based peptides; however, the kinetics of the individual hydrolysis reactions may differ significantly.

Second, caspase prodomains vary in length and sequence (Table I). Long prodomain caspases function as signal integrators for apoptotic or pro-inflammatory signals and contain sequence motifs that promote their interaction with activator molecules (Table I) (22, 23). The apoptotic initiators (caspase-2, -8, -9, and -10) generally act upstream of the small prodomain apoptotic executioners (caspase-3, -6, and -7) (7, 8, 23). By contrast, caspase-1 and caspase-11 function predominantly as cytokine processors (12, 16). Less is known about caspase-4, -5, -12, -13, and -14; however, these caspases demonstrate a higher degree of sequence similarity to caspase-1 than to the apoptotic caspases (4-8). Therefore, these caspases are grouped with the cytokine processors. Overall, caspase substrate specificity, prodomain length, and prodomain sequence determine caspase function.

    Caspase Activation
TOP
INTRODUCTION
Caspases and Apoptosis
Caspase Structure
Caspase Activation
Caspases and the Apoptotic...
Conclusion
REFERENCES

Because caspases exist as latent zymogens, the question remains as to how the zymogens are activated. Current evidence suggests that activation may proceed by autoactivation, transactivation, or proteolysis by other proteinases.

Affinity-labeling experiments demonstrate that caspase zymogens have low but detectable proteolytic activity, suggesting the potential for autoactivation under certain circumstances (24, 25). Furthermore, overexpression of wild type caspases, but not catalytically inactive mutants, results in caspase processing and activation, indicating that autoactivation may occur at high enzyme concentration (26).1 Forced oligomerization of procaspase-8, procaspase-9, or CED-3 facilitates zymogen autoactivation and promotes apoptosis (25, 27-30). This process may approximate zymogens and restrict their mobility, thereby increasing the local enzyme concentration and promoting autoactivation. In vivo, adapter molecules mediate oligomerization of long prodomain procaspases.

Adapter molecules link apoptotic sensors such as death receptors and mitochondria to procaspases. To accomplish this, adapters generally contain one domain that couples the adapter to the sensor and another that binds to long prodomain procaspases. These domains include death domains (DDs),2 death effector domains (DEDs), and caspase recruitment domains (CARDs) (Table I). DDs, DEDs, and CARDs all contain six anti-parallel alpha -helices arranged in a similar three-dimensional fold and associate via like-like interactions (31-33). However, hydrophobic interactions are important for DED-DED interactions, whereas electrostatic interactions are critical for CARD-CARD interactions (31-33).

The adapter molecule FADD couples the Fas death receptor to procaspase-8. FADD contains a DD that interacts with a similar domain on Fas and also contains a DED that binds to the DEDs of procaspase-8 (23). Fas activation stimulates binding of the receptor's DD to the corresponding domain in FADD, which in turn recruits procaspase-8 by a homophilic interaction involving DEDs. Subsequent oligomerization then promotes procaspase-8 autoactivation (Fig. 1) (23, 34, 35). FADD probably activates procaspase-10 through a similar mechanism (36). Interestingly, FLIP, a catalytically inactive caspase-8-like molecule with two DEDs, inhibits Fas-FADD-procaspase-8 interactions and thereby inhibits apoptosis (37).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Caspase activation mechanisms. Sensors convey activation signals to adapters that facilitate oligomerization and subsequent autoactivation of long prodomain caspases (1). Once activated, caspases transactivate other procaspases (2). Direct proteolysis by non-caspase proteinases may also promote procaspase activation (3). See the text for details.

Mitochondria sense apoptotic signals and convey them to the activation adapter APAF-1 via the release of cytochrome c. Cytochrome c binds to APAF-1, and in the presence of adenine nucleotides, the APAF-1-cytochrome c complex promotes activation of procaspase-9 (38). Cytochrome c and adenine nucleotides likely induce a conformational change that exposes the APAF-1 CARD domain. The exposed APAF-1 CARD domain can in turn recruit procaspase-9 by a homophilic interaction involving CARDs. Subsequent procaspase-9 oligomerization then facilitates caspase autoactivation. Bcl-XL, an anti-apoptotic Bcl-2 family protein, may inhibit apoptosis by blocking these interactions (39). A second CARD-containing adapter, RAIDD, couples procaspase-2 to death receptors via CARD-CARD interactions (40, 41). Thus, adapter-mediated protein-protein interactions are widespread among the apoptotic caspases.

Less is known about activation of pro-inflammatory caspases. CARDIAK, a CARD-containing kinase, promotes procaspase-1 activation in vitro via a CARD-CARD interaction, suggesting that CARD-mediated oligomerization could function in procaspase-1 activation (42). Ligation of the CD40 receptor also promotes procaspase-1 activation (43); however, whether CARDIAK facilitates this activation is unknown. Finally, caspase-11 does not directly process procaspase-1 but may facilitate zymogen activation by a non-proteolytic interaction (16).

Once activated, caspases transactivate other procaspases, providing the opportunity for cascade amplification and positive feedback. Caspase-8 for example efficiently activates procaspase-3 (kcat/Km = 8.7 × 105 M-1 s-1) (44), and active caspase-3 in turn may activate procaspase-8. Although this positive feedback loop is theoretically possible, it has not yet been demonstrated. Additionally, because caspases have varied substrate specificity, a single activated caspase may not directly activate all other family members. For example, caspase-9 activates procaspase-3 and procaspase-7 but cannot activate procaspase-6 (29). Propagation of a caspase cascade will thus depend on which caspases a cell expresses, the relative concentrations of each caspase, and the kinetic efficiency of the individual transactivation reactions.

Caspase activation by non-caspase proteinases represents another mechanism for activation. The cytotoxic T cell proteinase, granzyme B, an aspartate-specific serine proteinase, provides the best example of this concept as this enzyme can activate several caspases and potently induces apoptosis (44-48). This proteinase is an extremely efficient activator of procaspase-3 and procaspase-7 (kcat/Km, 4.8 × 106 M-1 s-1, 8.6 × 107 M-1 s-1, respectively) (44, 48). Remarkably, granzyme B activates procaspase-3 5.5 times faster than caspase-8 and 17 times faster than caspase-10 (44). A second serine proteinase, cathepsin G, efficiently activates procaspase-7 by cleaving after Gln-194, indicating that aspartate specificity is not required for caspase activation (48). However, cathepsin G has no known function in apoptosis. Several other proteinases including calpain, the proteasome, apoptotic serine proteinase p24, and cathepsin D have been implicated in apoptosis (49-52). Whether these proteinases directly or indirectly interact with caspases is unknown.

    Caspases and the Apoptotic Mechanism
TOP
INTRODUCTION
Caspases and Apoptosis
Caspase Structure
Caspase Activation
Caspases and the Apoptotic...
Conclusion
REFERENCES

Apoptotic cells die a stereotypical death, regardless of the initiating death signal (53). The cytoplasm shrinks, the plasma membrane blebs and vesiculates, and phosphatidylserine redistributes to the cell surface. Simultaneously, the nucleus shrinks, chromatin condenses, and DNA fragments into high molecular weight and oligonucleosomal pieces. Identification of caspase substrates has provided insight into how caspases promote these changes. Table II groups caspase substrates into five categories based on putative function and lists examples for each category. More extensive substrate lists are available elsewhere (7, 8, 54).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Apoptotic substrates
The abbreviations used are: DNA-PKCS, DNA protein kinase catalytic subunit; U1-70kDa, U1-specific 70-kDa protein; RFC-140, replication factor C; HnRNP, heteronuclear ribonucleoproteins; GDI, GDP dissociation inhibitor; cPLA2, cytoplasmic phospholipase A2; PARP, poly(ADP-ribose) polymerase.

Pro- and anti-apoptotic proteins are probably the first caspase targets following an apoptotic stimulus (Table II) (7, 8, 54). These cleavage events participate in signal amplification and inhibitor inactivation. For example, transactivation of procaspases could generate sufficient proteolytic activity to overwhelm endogenous caspase inhibitors such as inhibitor of apoptosis proteins. Caspase-3 cleaves Bcl-2 and Bcl-XL, which destroys the anti-apoptotic function of these proteins and releases C-terminal fragments that are pro-apoptotic. Similarly, caspase-8 cleaves BID, a pro-apoptotic Bcl-2 family member, releasing a C-terminal fragment that induces release of mitochondrial cytochrome c (55, 56). Caspase-8 also cleaves p28Bap31, a Bcl-2-associated protein present on the endoplasmic reticulum. This cleavage event may enhance apoptotic signaling because the N-terminal p28Bap31 fragment induces apoptosis. Thus, activated caspases have multiple avenues to enhance apoptotic signaling.

As the apoptotic signal propagates, caspases activate other components of the apoptotic machinery (Table II). These components likely include ICAD, gelsolin, PAK2, MEKK1, and PKCdelta (7, 8, 54). Proteolysis of these proteins directly impacts upon the apoptotic phenotype. For example, caspase-3 cleaves ICAD, prompting release of active CAD, which then cleaves DNA and promotes chromatin condensation. Caspase-3 also cleaves and activates gelsolin, a protein that regulates actin dynamics. Interestingly, activated gelsolin promotes both cytoplasmic and nuclear apoptosis, including DNA fragmentation. Caspase-dependent activation of kinases including PAK2, MEKK1, and PKCdelta also promotes cytoplasmic and nuclear apoptosis. Interestingly, MEKK1 activation enhances caspase activation, suggesting that kinases may amplify or initiate the caspase cascade.

Caspases also cleave structural proteins of the nucleus and cytoskeleton (Table II) (7, 8, 54, 57). Proteolysis of lamins, NuMa, and SAF-A likely promotes nuclear dissolution and packaging. Similarly, caspases may disrupt cytoskeletal integrity by proteolysis of fodrin, Gas2, keratins, Rabaptin-5, and actin. Cleavage of beta -catenin and FAK may interrupt cell-cell contacts and cell-matrix focal adhesions. Altogether, proteolysis of these caspase substrates may promote cellular packaging and subsequent engulfment by phagocytes. It should be noted, however, that the functions of these cleavage events are largely speculative and await a more rigorous evaluation.

Another class of caspase substrates includes proteins important for cellular signaling, cellular repair, and macromolecular synthesis. These proteins include kinases, other enzymes, and factors necessary for protein and nucleic acid synthesis (Table II) (7, 8, 54). Caspase-dependent proteolysis also promotes degradation of Akt-1 and Raf-1, kinases important for cell growth and survival (58). However, these proteins are not direct caspase substrates, suggesting that caspases may activate other proteinases that participate in apoptotic events (58). Overall, proteolysis of these proteins could disrupt cellular homeostasis and terminate survival signals; however, this has not yet been formally demonstrated.

Caspases also cleave presenilins, huntingtin, atrophin-1, and other proteins implicated in neurodegenerative disease (Table II) (7, 8, 54, 59-61). Some of these proteins are cleaved during apoptosis; however, the significance of these proteolytic events is not clear. Wellington et al. (59), however, suggest that caspase zymogens may cleave neurodegenerative proteins at a low level, generating toxic fragments that initiate apoptosis and perhaps neurodegenerative diseases.

    Conclusion
TOP
INTRODUCTION
Caspases and Apoptosis
Caspase Structure
Caspase Activation
Caspases and the Apoptotic...
Conclusion
REFERENCES

Numerous studies establish caspases as essential mediators of apoptosis. Because disordered apoptosis can promote human disease, these findings have broad implications. Insufficient apoptosis because of caspase inactivation may promote oncogenesis by allowing cell accumulation (62). Recent evidence supports this hypothesis, and careful study of the caspase knockout animals should provide more definitive answers to this question (12, 63). On the other hand, caspase over-reactivity promotes cellular suicide, and this may be the basis for degenerative diseases such as Huntington's disease and Alzheimer's disease (59-61). Net increases in apoptosis could result from a decreased apoptotic threshold, enhanced apoptotic stimulation, or a combination of these factors. Regardless of the inciting factor(s), enhanced caspase activity should result. On the molecular level, increased expression/activity of caspases, apoptotic sensors, or adapters or diminished expression/activity of caspase inhibitors could increase caspase activity. Similarly, loss of survival signals, mitochondrial dysfunction, or diminished stress responses might prompt caspase activation and apoptosis. Further study of the caspase system will prove or disprove these theories and will one day offer treatments for disorders of apoptosis.

    ACKNOWLEDGEMENTS

Because of space limitations, it was not possible to include a comprehensive list of references for all the work discussed. We apologize to those authors whose important contributions could not be described or properly cited.

    Note Added in Proof

Since this Minireview was accepted for publication, key studies concerning caspase activation and caspase involvement in human disease have been published. First, Stennicke et al. (64) established that caspase-9 activation does not require proteolytic processing of the zymogen and that the zymogen itself has significant activity in the presence of cytosolic cofactors (presumably APAF-1). Second, we demonstrated that calpain may regulate caspase-9 activation by removing the procaspase-9 CARD domain (65). Third, Yuan and colleagues (66) demonstrated that polyglutamine repeats induce neuronal cell death via caspase-8 and implicated caspase-8 in Huntington's disease, a polyglutamine repeat disease. Finally, Nicholson's group (67) implicated caspase-dependent processing of the amyloid-beta precursor protein in the pathogenesis of Alzheimer's disease.

    FOOTNOTES

* This minireview will be reprinted in the 1999 Minireview Compendium, which will be available in December, 1999. This is the first article of four in the "Proteases in Cellular Regulation Minireview Series."

Supported by National Institutes of Health Mentored Clinical Scientist Development Award CA75268-01.

parallel To whom correspondence should be addressed: La Jolla Inst. for Allergy and Immunology, 10355 Science Center Dr., San Diego, CA 92121. Tel.: 619-558-3500; Fax: 619-558-3525; E-mail: dgreen5240@aol.com.

1 H. R. Stennicke and G. S. Salvesen, personal communication.

    ABBREVIATIONS

The abbreviations used are: DD, death domain; DED, death effector domain; CARD, caspase recruitment domain; FADD, Fas-associated death domain; RAIDD, Rip-associated ICH-1/CED-3 homologous protein with a death domain; APAF-1, apoptotic protease-activating factor-1; CARDIAK, CARD-containing interleukin-1beta converting enzyme-associated kinase; CAD, caspase-activated DNase; ICAD, inhibitor of caspase-activated DNase; PAK2, p21-activated kinase 2; MEKK1, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1; PKC, protein kinase C; NuMa, nuclear mitotic apparatus protein; SAF-A, scaffold attachment factor A; Gas2, growth arrest specific gene 2; FAK, focal adhesion kinase.

    REFERENCES
TOP
INTRODUCTION
Caspases and Apoptosis
Caspase Structure
Caspase Activation
Caspases and the Apoptotic...
Conclusion
REFERENCES

1. Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M., and Horvitz, H. R. (1993) Cell 19, 641-652
2. Cerretti, D. P., Kozolosky, C. J., Mosley, B., Nelson, N., Van Ness, K., Greenstreet, T. A., March, C. J., Kronheim, S. R., Druck, T., Cannizzaro, L. A., Huebner, K., and Black, R. A. (1992) Science 256, 97-100[Abstract/Free Full Text]
3. Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., Wlliston, K. O., Ayala, J. M., Casano, F. J., Chin, J., Ding, G. J.-F., Egger, L. A., Gaffney, E. P., Limjuco, G., Palyha, O. C., Raju, S. M., Rolando, A. M., Salley, J. P., Yamin, T.-T., Lee, T. D., Shively, J. E., MacCross, M., Mumford, R. A., Schmidt, J. A., and Tocci, M. J. (1992) Nature 356, 768-774[CrossRef][Medline] [Order article via Infotrieve]
4. Van de Craen, M., Vandenabeele, P., Declercq, W., Van den Brande, I., Van Loo, G., Molemans, F., Schotte, P., Van Criekinge, W., Beyaert, R., and Fiers, W. (1997) FEBS Lett. 403, 61-69[CrossRef][Medline] [Order article via Infotrieve]
5. Humke, E. W., Ni, J., and Dixit, V. M. (1998) J. Biol. Chem. 273, 15702-15707[Abstract/Free Full Text]
6. Shimin, H., Snipas, S. J., Vincenz, C., Salvesen, G., and Dixit, V. M. (1998) J. Biol. Chem. 273, 29648-29653[Abstract/Free Full Text]
7. Cohen, G. M. (1997) Biochem. J. 326, 1-16
8. Nicholson, D. W., and Thornberry, N. A. (1997) Trends Biochem. Sci. 22, 299-306[CrossRef][Medline] [Order article via Infotrieve]
9. Bump, N. J., Hackett, M., Hugunin, M., Seshagiri, S., Brady, K., Chen, P., Ferenz, C., Franklin, S., Ghayur, T., Li, P., Licari, P., Mankovich, J., Shi, L., Greenberg, A. H., Miller, L. K., and Wong, W. W. (1995) Science 269, 1885-1888[Abstract/Free Full Text]
10. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, K. S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. (1995) Cell 81, 801-809[CrossRef][Medline] [Order article via Infotrieve]
11. Ellis, H., and Horvitz, H. R. (1986) Cell 44, 817-829[CrossRef][Medline] [Order article via Infotrieve]
12. Green, D. R. (1998) Cell 94, 695-698[CrossRef][Medline] [Order article via Infotrieve]
13. Varfolomeev, E. E., Schuchmann, M., Luria, V., Chiannikulchai, N., Beckmann, J. S., Mett, I. L., Rebrikov, D., Brodianski, V. M., Kemper, O. C., Kollet, O., Lapidot, T., Soffer, D., Sobe, T., Avraham, K. B., Boncharov, T., Holtmann, H., Lonai, P., and Wallach, D. (1998) Immunity 9, 267-276[CrossRef][Medline] [Order article via Infotrieve]
14. Song, Z., McCall, K., and Stellar, H. (1997) Science 275, 536-540[Abstract/Free Full Text]
15. Bergeron, L., Perez, G. I., Macdonald, G., Shi, L., Sun, Y., Jurisicova, A., Varmuza, S., Latham, K. E., Flaws, J. A., Salter, J. C. M., Hara, H., Moskowitz, M. A., Li, W., Greenberg, A., Tilly, J. L., and Yuan, J. (1998) Genes Dev. 12, 1304-1314[Abstract/Free Full Text]
16. Wang, S., Miura, M., Jung, Y., Zhu, H., Li, E., and Yuan, J. (1998) Cell 92, 501-509[CrossRef][Medline] [Order article via Infotrieve]
17. Walker, N. P. C., Talanian, R. V., Brady, K. D., Dang, L. C., Bump, N. J., Ferenz, C. R., Franklin, S., Ghayur, T., Hackett, M. C., Hammil, L. D., Herzog, L., Hugunin, M., Houy, W., Mankovich, J. A., McGuiness, L., Oriewicz, E., Paskind, M., Pratt, C. A., Reis, P., Summani, A., Terranova, M., Welch, J. P., Xiong, L., Moller, A., Tracey, D. E., Kamen, R., and Wong, W. W. (1994) Cell 78, 343-352[CrossRef][Medline] [Order article via Infotrieve]
18. Wilson, K. P., Black, J. F., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia, M. A., Murcko, M. A., Chambers, S. P., Aldape, R. A., Raybuck, S. A., and Livingston, D. J. (1994) Nature 370, 270-275[CrossRef][Medline] [Order article via Infotrieve]
19. Rotonda, J., Nicholson, D. W., Fazil, K. M., Gallant, M., Gareau, Y., Labelle, M., Peterson, E. P., Rasper, D. M., Ruel, R., Vaillancourt, J. P., Thornberry, N. A., and Becker, J. W. (1996) Nature Biotechnol. 3, 619-625
20. Mittl, P. R. E., Di Marco, S., Krebs, J. F., Bai, X., Karanewsky, D. S., Priestle, J. P., Tomaselli, K. J., and Grutter, M. G. (1997) J. Biol. Chem. 272, 6539-6547[Abstract/Free Full Text]
21. Thornberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., Garcia-Calvo, M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. P., Chapman, K. T., and Nicholson, D. W. (1997) J. Biol. Chem. 272, 17907-17911[Abstract/Free Full Text]
22. Hoffman, K., Bucher, P., and Tschopp, J. (1997) Trends Biochem. Sci. 22, 155-156[CrossRef][Medline] [Order article via Infotrieve]
23. Ashkenazi, A., and Dixit, V. M. (1998) Science 281, 1305-1308[Abstract/Free Full Text]
24. Yamin, T. T., Ayala, J. M., and Miller, D. K. (1996) J. Biol. Chem. 271, 13273-13282[Abstract/Free Full Text]
25. Muzio, M., Stockwell, B. R., Stennicke, H. R., Salvesen, G. S., and Dixit, V. M. (1998) J. Biol. Chem. 273, 2926-2930[Abstract/Free Full Text]
26. Orth, K., O'Rourke, K., Salvesen, G., and Dixit, V. M. (1996) J. Biol. Chem. 271, 20977-20980[Abstract/Free Full Text]
27. Martin, D. A., Siegel, R. M., Zheng, L., and Lenardo, M. J. (1998) J. Biol. Chem. 273, 4345-4349[Abstract/Free Full Text]
28. Yang, X., Chang, H. Y., and Baltimore, D. (1998) Mol. Cell 1, 319-325[CrossRef][Medline] [Order article via Infotrieve]
29. Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., and Alnemri, E. S. (1998) Mol. Cell 1, 949-957[CrossRef][Medline] [Order article via Infotrieve]
30. Yang, X., Chang, H. Y., and Baltimore, D. (1998) Science 281, 1355-1357[Abstract/Free Full Text]
31. Huang, B., Eberstadt, M., Olejniczak, E. T., Meadows, R. P., and Fesik, S. W. (1996) Nature 384, 638-641[CrossRef][Medline] [Order article via Infotrieve]
32. Eberstadt, M., Huang, B., Chen, Z., Meadows, R. P., Ng, S.-C., Zheng, L., Lenardo, M. J., and Fesik, S. W. (1998) Nature 392, 941-945[CrossRef][Medline] [Order article via Infotrieve]
33. Chou, J. J., Matsuo, H., Duan, H., and Wagner, G. (1998) Cell 94, 171-180[CrossRef][Medline] [Order article via Infotrieve]
34. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) Cell 85, 817-827[CrossRef][Medline] [Order article via Infotrieve]
35. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. (1996) Cell 85, 803-815[CrossRef][Medline] [Order article via Infotrieve]
36. Vincenz, C., and Dixit, V. M. (1997) J. Biol. Chem. 272, 6578-6583[Abstract/Free Full Text]
37. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J. L., Schreoter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., and Tschopp, J. (1997) Nature 388, 190-195[CrossRef][Medline] [Order article via Infotrieve]
38. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997) Cell 91, 470-489
39. Hu, Y., Benedict, M. A., Wu, D., Inohara, N., and Nunez, G. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4386-4391[Abstract/Free Full Text]
40. Duan, H., and Dixit, V. M. (1997) Nature 385, 86-89[CrossRef][Medline] [Order article via Infotrieve]
41. Ahmad, M., Srinivasula, S. M., Wang, L., Talanian, R. V., Litwack, G., Fernandes-Alnemri, T., and Alnemri, E. S. (1997) Cancer Res. 57, 615-619[Abstract/Free Full Text]
42. Thome, M., Hofmann, K., Burns, K., Martinon, F., Bodmer, J.-L., Mattmann, C., and Tschopp, J. (1998) Curr. Biol. 8, 885-888[CrossRef][Medline] [Order article via Infotrieve]
43. Schonbeck, U., Mach, F., Bonnefoy, J.-Y., Loppnow, H., Flad, H.-D., and Libby, P. (1997) J. Biol. Chem. 272, 19569-19574[Abstract/Free Full Text]
44. Stennicke, H. R., Jurgensmeier, J. M., Shin, H., Deveraux, Q., Wolf, B. B., Yang, X., Zhou, Q., Ellerby, H. M., Ellerby, L. M., Bredesen, D., Green, D. R., Reed, J. C., Froelich, C. J., and Salvesen, G. S. (1998) J. Biol. Chem. 273, 27084-27090[Abstract/Free Full Text]
45. Shresta, S., MacIvor, D. M., Heusel, J. W., Russell, J. H., and Ley, T. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5679-5683[Abstract/Free Full Text]
46. Simon, M. M., Hausmann, M., Tran, T., Ebnet, K., Tschopp, J., ThaHla, R., and Mullbacher, A. (1997) J. Exp. Med. 186, 1781-1786[Abstract/Free Full Text]
47. Darmon, A. J., Nicholson, D. W., and Bleackley, R. C. (1995) Nature 377, 446-448[CrossRef][Medline] [Order article via Infotrieve]
48. Zhou, Q., and Salvesen, G. S. (1997) Biochem. J. 324, 361-363
49. Squier, M. K. T., Miller, A. C. K., Malkinson, A. M., and Cohen, J. J. (1994) J. Cell. Physiol. 159, 229-237[CrossRef][Medline] [Order article via Infotrieve]
50. Wright, S. C., Wei, Q. S., Zhong, J., Zheng, H., Kinder, D. H., and Larrick, J. W. (1994) J. Exp. Med. 180, 2113-2123[Abstract/Free Full Text]
51. Hirsch, T., Dallaporta, B., Zamzami, N., Susin, S. A., Rafagnan, L., Marzo, I., Brenner, C., and Kroemer, G. (1998) J. Immunol. 161, 35-40[Abstract/Free Full Text]
52. Deiss, L. P., Galinka, H., Berissi, H., Cohen, O., and Kimichi, A. (1996) EMBO J. 15, 3861-3870[Medline] [Order article via Infotrieve]
53. Martin, S. J., Green, D. R., and Cotter, T. G. (1994) Trends Biochem. Sci. 19, 26-30[CrossRef][Medline] [Order article via Infotrieve]
54. Cryns, V., and Yuan, J. (1998) Genes Dev. 12, 1551-1570[Free Full Text]
55. Li, H., Zhu, H., Xu, C., and Yuan, J. (1998) Cell 94, 481-490[CrossRef][Medline] [Order article via Infotrieve]
56. Luo, X., Budihardjo, I., Slaughter, C., and Wang, X. (1998) Cell 94, 491-501[CrossRef][Medline] [Order article via Infotrieve]
57. Gohring, F., Schwab, B. L., Nicotera, P., Leist, M., and Fackelmayer, F. O. (1997) EMBO J. 16, 7361-7371[CrossRef][Medline] [Order article via Infotrieve]
58. Widmann, C., Gibson, S., and Johnson, G. L. (1998) J. Biol. Chem. 273, 7141-7147[Abstract/Free Full Text]
59. Wellington, C. L., Ellerby, L. M., Hackam, A. S., Margolis, R. L., Trifiro, M. A., Singaraja, R., McCutcheon, K., Salvesen, G. S., Propp, S. S., Bromm, M., Rowland, K. J., Zhang, T., Rasper, D., Roy, S., Thornberry, N., Pinsky, L., Kakizuka, A., Ross, C. A., Nicholson, D. W., Bredesen, D. E., and Hayden, M. R. (1998) J. Biol. Chem. 273, 9158-9167[Abstract/Free Full Text]
60. Goldberg, Y. P., Nicholson, D. W., Rasper, D. M., Kalchman, M. A., Koide, H. B., Graham, R. K., Bromm, M., Kazemi-Esfarjani, P., Thornberry, N. A., Vaillancourt, J. P., and Hayden, M. R. (1996) Nat. Genet. 13, 442-449[CrossRef][Medline] [Order article via Infotrieve]
61. Wolozin, B., Iwasaki, K., Vito, P., Ganjei, J. K., Lacan, E., Sunderland, T., Zhao, B., Kusiak, J. W., Wasco, W., and D'Adamio, L. (1996) Science 274, 1710-1713[Abstract/Free Full Text]
62. Martin, S. J., and Green, D. R. (1996) Cell 82, 349-352
63. Resnicoff, M., Valentinis, B., Herbert, D., Abraham, D., Friesen, P. D., Alnemri, E. S., and Baserga, R. (1998) J. Biol. Chem. 273, 10376-10380[Abstract/Free Full Text]
64. Stennicke, H. R., Deveraux, Q. L., Humke, E. W., Reed, J. C., Dixit, V. M., and Salvesen, G. S. (1999) J. Biol. Chem. 274, 8359-8362[Abstract/Free Full Text]
65. Wolf, B. B., Goldstein, J. C., Stennicke, H. R., Beere, H., Amarante-Mendes, G., Salvesen, G. S., and Green, D. R. (1999) Blood, in press
66. Sanchez, I., Xu, C.-J., Juo, P., Kakizaka, A., Blenis, J., and Yuan, J. (1999) Neuron 22, 623-633[CrossRef][Medline] [Order article via Infotrieve]
67. Gervais, G. G., Xu, D., Robertson, G. S., Vaillancourt, J. P., Zhu, Y., Huang, J., LeBlanc, A., Smith, D., Rigby, M., Shearman, M. S., Clarke, E. E., Zheng, H., Van Der Ploeg, L. H. T., Ruffolo, S. C., Thornberry, N. A., Xanthoudakis, S., Zamboni, R. J., Roy, S., and Nicholson, D. W. (1999) Cell 97, 395-406[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
L. Kongkaneramit, N. Sarisuta, N. Azad, Y. Lu, A. K. V. Iyer, L. Wang, and Y. Rojanasakul
Dependence of Reactive Oxygen Species and FLICE Inhibitory Protein on Lipofectamine-Induced Apoptosis in Human Lung Epithelial Cells
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 969 - 977.
[Abstract] [Full Text] [PDF]


Home page
J Exp BotHome page
L. Bonneau, Y. Ge, G. E. Drury, and P. Gallois
What happened to plant caspases?
J. Exp. Bot., February 13, 2008; (2008) erm352v1.
[Abstract] [Full Text] [PDF]


Home page
J Exp BotHome page
T. J. Reape, E. M. Molony, and P. F. McCabe
Programmed cell death in plants: distinguishing between different modes
J. Exp. Bot., February 5, 2008; (2008) erm258v1.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. A. da Costa Martins and L. J. De Windt
Nix: The Cardiac Styx Between Life and Death
Circulation, January 22, 2008; 117(3): 338 - 340.
[Full Text] [PDF]


Home page
IOVSHome page
O. Perche, M. Doly, and I. Ranchon-Cole
Caspase-Dependent Apoptosis in Light-Induced Retinal Degeneration
Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2753 - 2759.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y.-A. Kim, D. Xiao, H. Xiao, A. A. Powolny, K. L. Lew, M. L. Reilly, Y. Zeng, Z. Wang, and S. V. Singh
Mitochondria-mediated apoptosis by diallyl trisulfide in human prostate cancer cells is associated with generation of reactive oxygen species and regulated by Bax/Bak
Mol. Cancer Ther., May 1, 2007; 6(5): 1599 - 1609.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. M. Mohammad, A. S. Goustin, A. Aboukameel, B. Chen, S. Banerjee, G. Wang, Z. Nikolovska-Coleska, S. Wang, and A. Al-Katib
Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1
Clin. Cancer Res., April 1, 2007; 13(7): 2226 - 2235.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. J. Son, M. H. Park, S. J. Chae, S. O. Moon, J. W. Lee, H. S. Song, D. C. Moon, S. S. Kang, Y. E. Kwon, and J. T. Hong
Inhibitory effect of snake venom toxin from Vipera lebetina turanica on hormone-refractory human prostate cancer cell growth: induction of apoptosis through inactivation of nuclear factor {kappa}B
Mol. Cancer Ther., February 1, 2007; 6(2): 675 - 683.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. Xiao, V. Vogel, and S. V. Singh
Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak.
Mol. Cancer Ther., November 1, 2006; 5(11): 2931 - 2945.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. F. Voelkel, R. A. Quaife, L. A. Leinwand, R. J. Barst, M. D. McGoon, D. R. Meldrum, J. Dupuis, C. S. Long, L. J. Rubin, F. W. Smart, et al.
Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.
Circulation, October 24, 2006; 114(17): 1883 - 1891.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. T. Page, D. W. Lin, E. A. Mostaghel, D. L. Hess, L. D. True, J. K. Amory, P. S. Nelson, A. M. Matsumoto, and W. J. Bremner
Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3850 - 3856.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. K. Mantena, S. D. Sharma, and S. K. Katiyar
Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP
Carcinogenesis, October 1, 2006; 27(10): 2018 - 2027.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
B. Dursun, Z. He, H. Somerset, D.-J. Oh, S. Faubel, and C. L. Edelstein
Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis
Am J Physiol Renal Physiol, September 1, 2006; 291(3): F578 - F587.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
S. Zheng, T. T. Turner, and J. J. Lysiak
Caspase 2 Activity Contributes to the Initial Wave of Germ Cell Apoptosis During the First Round of Spermatogenesis
Biol Reprod, June 1, 2006; 74(6): 1026 - 1033.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Ishihara and N. Shimamoto
Involvement of Endonuclease G in Nucleosomal DNA Fragmentation under Sustained Endogenous Oxidative Stress
J. Biol. Chem., March 10, 2006; 281(10): 6726 - 6733.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. A. Mareninova, K.-F. Sung, P. Hong, A. Lugea, S. J. Pandol, I. Gukovsky, and A. S. Gukovskaya
Cell Death in Pancreatitis: CASPASES PROTECT FROM NECROTIZING PANCREATITIS
J. Biol. Chem., February 10, 2006; 281(6): 3370 - 3381.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. K. Mantena, S. D. Sharma, and S. K. Katiyar
Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells.
Mol. Cancer Ther., February 1, 2006; 5(2): 296 - 308.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
A. Balasubramanian, N. Munshi, M. J. Koziel, Z. Hu, T. J. Liang, J. E. Groopman, and R. K. Ganju
Structural proteins of Hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells
J. Gen. Virol., December 1, 2005; 86(12): 3291 - 3301.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. V. Singh, Y. Zeng, D. Xiao, V. G. Vogel, J. B. Nelson, R. Dhir, and Y. B. Tripathi
Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak
Mol. Cancer Ther., November 1, 2005; 4(11): 1747 - 1754.
[Abstract] [Full Text] [PDF]